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Abstract
Purpose: Dendritic cell (DC) vaccines have recently emerged as an innovative therapeutic option for glioblastoma patients.
To identify novel surrogates of anti-tumor immune responsiveness, we studied the dynamic expression of activation and
inhibitory markers on peripheral blood lymphocyte (PBL) subsets in glioblastoma patients treated with DC vaccination at
UCLA.
Experimental Design: Pre-treatment and post-treatment PBL from 24 patients enrolled in two Phase I clinical trials of
dendritic cell immunotherapy were stained and analyzed using flow cytometry. A univariate Cox proportional hazards
model was utilized to investigate the association between continuous immune monitoring variables and survival. Finally,
the immune monitoring variables were dichotomized and a recursive partitioning survival tree was built to obtain cut-off
values predictive of survival.
Results: The change in regulatory T cell (CD3
+CD4
+CD25
+CD127
low) frequency in PBL was significantly associated with
survival (p=0.0228; hazard ratio=3.623) after DC vaccination. Furthermore, the dynamic expression of the negative co-
stimulatory molecule, CTLA-4, was also significantly associated with survival on CD3
+CD4
+ T cells (p=0.0191; hazard
ratio=2.840) and CD3
+CD8
+ T cells (p=0.0273; hazard ratio=2.690), while that of activation markers (CD25, CD69) was not.
Finally, a recursive partitioning tree algorithm was utilized to dichotomize the post/pre fold change immune monitoring
variables. The resultant cut-off values from these immune monitoring variables could effectively segregate these patients
into groups with significantly different overall survival curves.
Conclusions: Our results suggest that monitoring the change in regulatory T cell frequencies and dynamic expression of the
negative co-stimulatory molecules on peripheral blood T cells, before and after DC vaccination, may predict survival. The
cut-off point generated from these data can be utilized in future prospective immunotherapy trials to further evaluate its
predictive validity.
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Introduction
Glioblastoma is one of the most lethal of human cancers, with
very few long-term survivors and no definitive cures for this
disease. These tumors invade and infiltrate the surrounding brain,
making complete surgical excision impossible. They are also
among the most radiation and chemotherapy resistant cancers,
with a median survival of 12–18 months from initial diagnosis,
even with surgery, radiation and chemotherapy [1,2,3,4,5]. The
glioblastoma patient population has dismal outcomes and
innovative approaches are desperately needed. Thus, glioblastoma
remains a largely unmet medical need, and highlights the need for
novel and effective therapies.
Recently, there has been a growing interest in applying tumor
immunotherapy approaches to primary brain tumors, based on
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e32614the recent FDA approvals for Sipuleucel-T in prostate cancer and
Ipilumimab for metastatic melanoma [6,7,8,9]. Immunotherapy is
theoretically appealing because it offers the potential for a high
degree of tumor-specificity, while sparing normal brain structures
[10]. One such approach uses professional antigen-presenting
cells, known as dendritic cells (DC), co-cultured with autologous
tumor lysate or glioma-associated antigens to target these tumors
immunologically. Initial studies of DC-based vaccine therapy for
malignant gliomas have shown acceptable safety and toxicity
profiles [11,12,13,14,15,16,17,18,19,20,21,22], and multi-center
randomized Phase II and III studies are currently underway.
While DC vaccine strategies have shown great promise
[14,15,16,21,22,23], there are still many barriers and uncertainties
associated with this treatment modality. One of the prominent
barriers of immunotherapy is the absence of biomarkers, imaging
modalities and/or peripheral blood immune monitoring assays
that can convey relevant information about anti-tumor immune
responses elicited by the therapy. Many vaccine-based approaches
consider the expansion of antigen-specific T cells, with functional
activation characteristics, as the most important surrogates of
efficacy. However, the majority of these immune monitoring
strategies have not yielded an association with the clinical effects.
The complexity of the treatments and patients, as well as the array
of distinct monitoring assays, has not led to any uniform surrogate
for immunotherapy.
Such history prompted us to analyze peripheral blood
lymphocyte (PBL) populations for immunoregulatory factors that
might be associated with predicting prognosis and monitoring
patient progress after dendritic cell vaccination. We focused on the
pattern of regulatory T (Treg) cell frequencies and negative co-
stimulatory molecule expression on PBL, before and after DC
vaccination. Treg cells play an essential role in lymphocyte
development by maintaining tolerance and suppressing lympho-
cyte function [24]. Several groups have provided evidence that
Treg cells accumulate in gliomas and suppress the anti tumor
immune response [25,26,27,28,29,30,31,32]. We also evaluated
the dynamic expression of the negative co-stimulatory molecules
(CTLA-4 and PD-1) on several cell populations. CTLA-4 and PD-
1 both play essential roles in the regulation of peripheral tolerance
by limiting T-cell activation and downstream signaling [33]. When
CTLA-4 is upregulated on the surface of T-cells it can bind B7 co-
stimulatory molecules with a higher affinity than CD28,
preventing the initiation of T-cell activation [33]. In essence,
CTLA-4 and Treg cells both function to down regulate the
lymphocyte immune response. With a larger understanding of
Treg cells and negative co-stimulatory molecules, we focused our
research on examining their frequencies in peripheral lymphocyte
populations. We found that decreased Treg cell populations and
decreased expression of CTLA-4 on peripheral blood T cells, after
DC vaccination, were correlated with longer survival in glioblas-
toma patients.
Materials and Methods
Patient Eligibility
This study focuses on 24 patients diagnosed with glioblastoma at
our institution and treated with either autologous tumor lysate-
pulsed (UCLA IRB #03-04-053, FDA IND #11053, clinical trial
registration # NCT00068515) or glioma-associated antigen
(GAA) peptide-pulsed (UCLA IRB #06-01-052, FDA IND
#12966, clinical trial registration # NCT00612001) DC vacci-
nation between 2003 and 2010. All patients provided written
informed consent for studies approved by the UCLA Medical
Institutional Review Board (IRB) prior to treatment. This
informed consent was approved by the UCLA Medical IRB and
given by patients for their experimental treatment, for a database
that stored clinical data, and for research performed on remnant
patient tissues. Patient inclusion/exclusion criteria have been
published [14,16,34] and can be found at ClinicalTrials.gov for
these studies (http://clinicaltrials.gov/).
Preparation of Autologous Dendritic Cells and Pulsing
with Glioma Antigen
Monocyte-derived DCs were established from adherent periph-
eralbloodmononuclearcells(PBMC)obtainedvialeukapheresis,as
we have recently published [16]. All ex vivo DC preparations were
performedintheUCLA-JonssonCancerCenterGMPfacilityunder
sterile and monitored conditions. Briefly, dendritic cells were
prepared by culturing adherent PBMC in RPMI-1640 (Gibco) and
supplemented with 10% autologous serum, 500 U/mL GM-CSF
(LeukineH, Amgen, Thousand Oaks, CA) and 500 U/mL of IL-4
(CellGenix). For the GAA peptide trial, DC were additionally
maturedwithaclinical-gradecocktailof10 ng/mlTNF-a,10 ng/ml
IL-1b, 150 ng/ml IL-6 (all from CellGenix), and 1 mg/ml prosta-
glandin E2 (Sigma) for 24–48 hours [35]. Following culture, DCs
were collected by vigorous rinsing and subsequently washed with
sterile0.9%NaClsolution.ThepurityandphenotypeofeachDClot
was also determined by flow cytometry (FACScan flow cytometer;
BD Biosciences, San Jose, CA). Cells were stained with FITC-
conjugated CD83, PE-conjugated CD86 and PerCP-conjugated
HLA-DR mAb’s (BD Biosciences). Release criteria were .70%
viablebytrypanblueexclusion,and.30%ofthelargecellgatebeing
CD86
+ and HLA-DR
+. DC were pulsed (co-cultured) with either
tumor lysate overnight or the HLA-A0201 restricted peptides
gp100209–217(209M),TRP-2180–188,Survivin96–104,Her-2/neu369–377
(ClinAlfa/Biosynthesis, Inc.) and KLH (biosyn Corporation) for
90 minutes prior to washing and injection. The final product was
testedforsterilitybyGramstain,mycoplasmaandendotoxinpriorto
injection.
Treatment Schema
Newly diagnosed glioblastoma patients underwent surgery and
a standard course of external beam radiotherapy with concurrent
temozolomide chemotherapy prior to DC vaccination [4]. These
patients were given three biweekly DC vaccinations following
standard chemo-radiation and prior to adjuvant temozolomide
treatment. Recurrent glioblastoma patients had previous radiation
therapy and chemotherapy prior to presenting with tumor
recurrence, so they underwent surgical resection of their tumors
followed by DC immunotherapy after they had recovered from
surgery and were tapered off peri-operative steroids.
Vaccine Administration
On the day of each DC vaccination, a 1 ml vaccine dose was
drawn into a sterile tuberculin syringe and administered as an
intradermal (i.d.) injection (using a 25-gauge needle) in the arm
region below the axilla, with the side of administration rotated for
each vaccination. Subjects were monitored for two hours post-
immunization in the UCLA General Clinical Research Center
(GCRC). Eligible patients initially received three (3) intradermal
injections at biweekly intervals. All patients had a baseline brain
MRI scan within one month prior to starting the immunotherapy
and every two months thereafter or when clinically indicated.
Collection of PBMC for Immune Monitoring
Peripheral blood was drawn from patients at various time points
both pre and post DC vaccination. Once drawn, the peripheral
Immune Monitoring after DC Vaccination
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were harvested through subsequent extraction with Ficoll. After a
series of three washes in HBSS media, the cells were placed in a
freezing media of 10% DMSO and 90% serum and stored in
liquid nitrogen.
Antibody Staining of PBMC
Normal donor PBMC and patient PBMC were thawed at 37uC
for five minutes then immediately transferred to 10 ml RPMI
media and subsequently centrifuged at 4uC at 1070 RPM for five
minutes to remove DMSO from the freezing solution. The cell
pellet was resuspended with 5 ml RPMI and counted using a
hemocytometer and a light microscope. After counting, the
samples were centrifuged using the same settings and resuspended
at five million cells/ml PBS.
A normal PBMC negative control (one well), single color
compensation controls (eight wells), and experimental samples
(one well/sample) were then plated at one million cells per well
(200 ml) in a 96-well round bottom plate. In our experiment, two
sets of the experimental samples were plated, as two different
antibody cocktails (an eight-color combination and a seven-color
combination) were necessary to investigate all of the surface
markers of interest due to the spectral limitations of the flow
cytometer. The plate was then centrifuged (same settings),
decanted and resuspended in prepared antibody cocktails and
stained in the dark on ice for 30 min. Antibody cocktails were
prepared according to manufacturer specifications, usually 5 ml
antibody/50 ml FACS buffer for single color compensation
controls. The negative control was resuspended in 50 ml staining
buffer. The eight-color combination antibody cocktail contained
CD3 Texas Red (Invitrogen, Cat. MHCD0317), CD4 Alexa Fluor
700 (BD Biosystems, Cat. 557922), CD8 Pacific Blue (BD
Biosystems, Cat. 558207), CD16 FITC (BD Biosystems, Cat.
555406), CD19 PE (BD Biosystems, Cat. 555413), CD25 APC
Cy7 (BD Biosystems, Cat. 557753), CD127 AF647 (BD Biosys-
tems, Cat. 558598), and CD69 PE-CY5 (BD Biosystems, Cat.
555532) antibodies in the same amount used in the single color
control in 50 ml staining buffer/patient. The seven-color combi-
nation antibody cocktail contained CD3 Texas Red (Invitrogen,
Cat. MHCD0317), CD4 Alexa Fluor 700 (BD Biosystems, Cat.
557922), CD8 Pacific Blue (BD Biosystems, Cat. 558207), CD16
FITC (BD Biosystems, Cat. 555406), CTLA-4 PE (BD Biosystems,
Cat. 555853), PD-1 AF647 (eBioscience, Cat. 51-9969-73), and
CD69 PE-CY5 (BD Biosystems, Cat. 555532) antibodies in the
same amount used in the single color control in 50 ml staining
buffer/patient. The plate was then centrifuged (same settings),
decanted and resuspended with IC-Fixation buffer and stored in
the dark on ice for ten minutes. The plate was then centrifuged
(same settings), decanted and resuspended in 200 ml staining
buffer. Samples were then transferred to labeled flow tubes with an
additional 200 ml staining buffer, capped and stored at 4uC.
Flow Cytometric Analysis of PBMC
All samples were analyzed using the BD LSR II flow cytometer
and BD FACS diva software. Cytometer settings were set such that
only the eight colors used were present. The negative control was
then acquired and FSC and SSC voltages were adjusted such that
the lymphocyte population was visible. The single color compen-
sation controls were then acquired and voltages were adjusted
such that the stained cells did not exceed 10
4. A gate was set on
stained controls in comparison to the negative control and then
each sample was recorded and all compensation controls were
applied. Samples were then recorded at 500,000 events per
sample. Data acquired from the flow cytometer was analyzed
using FlowJo software. The lymphocyte population was gated and
then the lymphocyte subsets were gated: CD3
+CD4
+ Helper T
cells, CD3
+CD8
+ cytotoxic T cells, CD3
-CD16
+ classical Natural
Killer (NK) cells, CD3
+CD16
+ NKT cells, CD3
-CD19
+ B cells,
CD3
+CD25
+CD127
low Treg cells. The activation status and
expression of negative co-stimulatory molecules on these PBMC
were also evaluated by measuring the frequency of CD25, CD69,
CTLA-4 and PD-1.
Statistical Analysis
The raw data was aggregated and tabulated for analysis and
study using GraphPad software v5.03 (GraphPad Software, La
Jolla, CA). Descriptive statistics such as mean and standard
deviation were used to summarize continuous variables, while
count and percentage were used for categorical variables. Bivariate
comparisons of continuous variables and categorical variables
were performed using unpaired t-tests or Fisher’s exact tests,
respectively. The Kaplan Meier method and log-rank test were
used to summarize and compare the overall survival and time to
progression between trials. A univariate Cox proportional hazards
regression model was used to correlate the individual immune
monitoring variables with overall survival. A recursive partitioning
survival tree was built to obtain the cut-off values utilized to
dichotomize each immune monitoring variable, which could
differentiate the overall survival between the variables. For all
statistical investigations, tests for significance were two tailed, with
a statistically significant p-value threshold of 0.05. Statistical
analyses were performed using SAS 9.2 (SAS institute, Cary, NC).
Results
Patient Characteristics
Twenty-four patients with histologically diagnosed glioblastoma
(WHO Grade IV) were enrolled and treated in two Phase 1
clinical trials at UCLA. There were five women and nineteen men,
with an age range from 27 to 71 years of age (mean age of
48 years). Nineteen patients underwent treatment with autologous
tumor lysate pulsed DC vaccination (ATL DC) while five patients
underwent GAA peptide pulsed DC immunotherapy (GAA DC).
There was no significant age difference in the ATL DC versus the
GAA DC cohorts (48 vs. 43 years, p=0.52). Figure 1 outlines the
treatment schema used in these two clinical trials.
Overall Survival and Time to Tumor Progression
The median overall survival (OS) in the ATL DC vaccine group
was 33.8 months, while that of the GAA DC group was
14.5 months. Several of the ATL DC patients were long-term
survivors whereas all of the patients undergoing GAA DC therapy
died during the follow up period. The median time to tumor
progression (TTP) in the ATL DC vaccine therapy cohort was
13.9 months, while that of the GAA DC vaccine cohort was
9.6 months. The median OS and TTP for both groups together
was 23.0 and 13.1 months, respectively.
Lymphocyte Activation Markers are not Associated with
Survival after DC Vaccination in Glioblastoma Patients
Using a multi-color panel of fluorescently conjugated antibod-
ies, we were able to differentiate six specific cell populations
(CD3
+CD4
+ helper T cells, CD3
+CD8
+ cytotoxic T cells,
CD3
-CD16
+ NK cells, CD3
+CD16
+ NKT cells, CD3
-CD19
+ B
cells, CD3
+CD4
+CD25
+CD127
low regulatory T cells) within the
peripheral blood of patients in both the ATL and GAA peptide
DC trials (Figure 2). In each cell subset, we evaluated the
expression of activation (CD25, CD69) and negative costimulatory
Immune Monitoring after DC Vaccination
PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e32614markers (PD-1, CTLA-4). To account for the heterogeneity in
patient PBL populations before, and after DC vaccination,
comparisons were made from pre to post DC vaccination for
each patient, in order to create fold changes. We then examined
these fold changes in each lymphocyte subset and looked for
statistically significant relationships.
No significant changes were observed in any lymphocyte subset
frequency before and after DC vaccination (Table 1). In a recent
DC vaccination study, Ardon, et al., could not find any positive
correlation between immune reactivity and clinical outcome in
patients vaccinated with autologous tumor lysate-pulsed DC
vaccination [23]. Similarly, we also did not find any statistically
significant relationship between the activation status of any
lymphocyte subsets and survival (data not shown). These results
suggest that a complex interplay may be involved in the
immunoregulatory aspects of the overall anti-tumor immune
response.
Changes in Regulatory T cell Populations are Associated
with Extended Survival in Glioblastoma Patients after DC
Vaccination
Pre-clinical models of glioma have suggested that regulatory T
(Treg) cell populations can impact anti-tumor immune respon-
siveness [25,28,29,31,36,37] and pilot clinical studies suggest that
depletion of Treg cells in glioblastoma patients may be associated
with enhanced vaccine efficacy [38]. However, no published
literature has examined whether Treg cell populations are altered
in glioblastoma patients after DC vaccination, and whether any
differences have clinical ramifications. We used a cell surface
staining protocol to identify Treg cell populations in human PBL
[39,40] so that we could track this cell population before and
after DC vaccination in malignant glioma patients (Figure 3).
We then evaluated whether the fold change of Treg cell
frequency was associated with survival in these patients. Using
a univariate Cox proportional hazards model, we discovered a
highly significant relationship between Treg cell frequency
changes and survival (hazard ratio=3.623; 95% C.I. (1.196,
10.976); Table 2). Based on this statistical assessment, every
single unit increase in the Treg cell ratio is associated with an
increased risk of death by 2.623 times (3.623-1). This increase is
statistically significant (p=0.0228). These findings suggest that
Figure 1. Treatment and PBMC sampling schema of newly diagnosed and recurrent GBM patients. *Surgery, external beam radiotherapy
(XRT) and concurrent temozolomide chemotherapy was given per standard of care prior to DC vaccination in newly diagnosed glioblastoma patients.
Recurrent patients were treated with surgical resection and then enrolled immediately to the DC trial. Such patients did not receive concurrent XRT
and temozolomide. Leukapheresis was performed two weeks prior to vaccination followed by preparation of the DC vaccine one week prior to
vaccination. Three doses were administered intradermally (i.d.) at biweekly intervals. A follow up MRI was then performed two months after the start
of immunotherapy or when clinically indicated. PBMC sampling was performed by peripheral blood draw prior to each vaccination and again at day
42.
doi:10.1371/journal.pone.0032614.g001
Figure 2. FACS-based immune monitoring strategy in DC
vaccine patients. PBMC were isolated by ficoll separation prior to,
and after three bi-weekly DC vaccinations, frozen, and subsequently
thawed for staining simultaneously. Using a multi-color mAb cocktail,
six distinct lymphocyte populations were identified. In each population,
the expression of activation markers (CD69, CD25) and negative co-
stimulatory factors (PD-1, CTLA-4) were also evaluated.
doi:10.1371/journal.pone.0032614.g002
Table 1. Lymphocyte Subset Changes (Pre-Post) DC
Vaccination.
Lymphocyte Subset* Pre-Tx (Avg %) Post-Tx (Avg %)
CD3
+CD4
+ Helper T cells 38.8 37.6
CD3
+CD8
+ CTL 25.9 24.4
CD3
+CD16
+ NK T cells 5.4 4.7
CD3
2CD16
+ NK cells 11.5 14.1
CD3
2CD19
+ 9.5 9.9
CD3
+CD4
+CD25
+CD127
low Treg 19.1 18.2
*Percent of cells stained from ficoll-isolated PBMC at each time point.
doi:10.1371/journal.pone.0032614.t001
Immune Monitoring after DC Vaccination
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frequency decreases after DC vaccination.
Dynamic Changes in the Expression of CTLA-4 are
Associated with Survival in Glioblastoma Patients Treated
with DC Vaccination
The inhibitory costimulatory molecules, CTLA-4 and PD-1, are
known to impact anti-tumor immune responsiveness in murine
tumor models (reviewed in [33]), including gliomas [41]. In fact,
the use of a blocking antibody to CTLA-4 (Ipilumimab) in
metastatic melanoma patients demonstrated clinical efficacy [7]
and was recently given approval by the FDA [9]. To test whether
the expression of negative co-stimulatory molecules was altered in
glioblastoma patients receiving DC vaccination, we stained pre
and post vaccination PBL. The expression of PD-1 on any PBL
subset was not significantly altered after DC vaccination and did
not correlate with survival in these patients (data not shown).
However, a significant association with survival was discovered for
the expression of CTLA-4 by CD3
+CD4
+ T cells (Hazard Ratio
for death=2.84; p=0.0191) and CD3
+CD8
+ T cells (Hazard
Ratio for death=2.174; p=0.0460) in these patients (Figure 4,
Table 2). These findings suggest that extended survival is
observed in patients whose expression of CTLA-4 decreases in
helper and cytotoxic T cells after DC vaccination.
Estimated Post/pre Treatment Ratios for Treg Cell
Frequencies and CTLA-4 Expression Significantly
Dichotomize the Survival of Glioblastoma Patients
Receiving DC Vaccination
To develop a predictive immune monitoring tool for patients
treated with DC vaccination, we utilized a recursive partitioning
survival tree to dichotomize the immune monitoring ratio
Figure 3. Decreased frequencies of Treg cells after DC vaccination are associated with extended survival. PBMC from pre and post-DC
vaccination time points were stained with an antibody cocktail that identifies Treg cell populations (CD3
+CD4
+CD25
+CD127
low). The ratio of post
vaccination/pre-vaccination Treg cell frequencies from each patient was calculated and linked with the overall survival of each patient. (A) Flow
cytometric analysis of Treg cell populations from a normal volunteer. (B) Representative FACS plots of Treg cell frequencies from two glioblastoma
patients (7–799, 32–204) before and after DC vaccination.
doi:10.1371/journal.pone.0032614.g003
Table 2. Univariate Cox proportional hazards model for overall survival with each immune monitoring ratio.
Variable Cut-off point P-value for log-rank test (OS)
Treg cells (dichotomized) 0.8865 0.0074 (See Fig. 5a)
CD4
+ T cells w/CTLA-4 (dichotomized) 1.047 0.0034 (See Fig. 5b)
CD8
+ T cells w/CTLA-4 (dichotomized) 0.8065 0.0105 (See Fig. 5c)
Activated CD8
+ T cells (dichotomized) 0.703 0.0926
doi:10.1371/journal.pone.0032614.t002
Immune Monitoring after DC Vaccination
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below the calculated cut-off. As shown in Table 3 and Figure 5,
significant differences in survival were found when DC vaccine
patients were stratified by these estimated cut-off values for Treg
cell fractions and CTLA-4. These data suggest that DC-vaccinated
glioblastoma patients, whose Treg cell frequency or ratio of
CTLA-4 expression (post-Tx:Pre-Tx) is below the cut-off value,
will have extended survival.
Discussion
In the present study, we analyzed the relationship between
several immune monitoring variables and the survival of two
cohorts of glioblastoma patients treated with dendritic cell
vaccination. This study is one of the largest studies reported to
date comparing the outcomes of different DC vaccine patient
cohorts from a uniform population. Our results strongly suggest
that the balance of regulatory T cell frequencies and expression of
negative co-stimulatory molecules on peripheral blood T cells can
influence relevant anti-tumor immune responses in this patient
population. In addition, the development of an estimated post-
treatment/pre-treatment cut-off point ratio for each immune
monitoring variable may provide a segue to the design of
prospectively designed trials where we can test its clinical
relevance. As such, these tools can be incorporated and used to
evaluate and compare different monitoring strategies.
Our results also suggest that the dendritic cell vaccine platform
could be augmented by other biological therapies that influence
Treg cell populations and negative costimulatory molecules.
Increased post vaccination frequencies of Treg cell populations
were associated with shorter survival in our glioblastoma patients
who received the DC vaccination (Table 2). These findings are
consistent with the current understanding that Treg cells play a
significant role in down regulating the anti-tumor immune
response. Therefore, it follows that patients with lower levels of
Treg cells post vaccination should have stronger immune
responses and consequently longer survival. In support of this,
Mitchell, et al, recently demonstrated that immune responses were
dramatically enhanced after dendritic cell vaccination in glioblas-
toma patients that received IL-2Ra mAb blockade (daclizumab,
Roche Pharmaceuticals) and temozolomide chemotherapy [38].
Such data is consistent with recent reports that natural Treg cells
predominate inside gliomas, suggesting that the peripheral
Figure 4. Decreased expression of CTLA-4 on CD3
+CD4
+ and CD3
+CD8
+ T cells after DC vaccination is associated with extended
survival. PBMC from pre and post-DC vaccination time points were stained with an antibody cocktail that identifies CD4 and CD8 T cell populations
(CD3
+CD4
+or CD3
+CD8
+) and evaluated for the expression of CTLA-4. The ratio of post vaccination/pre-vaccination expression of CTLA-4 from each
patient was calculated and linked with the overall survival of each patient. (A) Flow cytometric analysis of CD3
+CD4
+ T cell expression of CTLA-4 from
a normal volunteer. (B) Representative FACS plots of CTLA-4 expression from CD3
+CD4
+ T cells in two glioblastoma patients (4–908, 21–828) before
and after DC vaccination.
doi:10.1371/journal.pone.0032614.g004
Table 3. Dichotomization of overall survival with each
immune monitoring ratio.
Variable Estimated HR P-value 95% CI
Treg cells 3.623 0.0228 (1.196, 10.976)
CD4
+ T cells w/CTLA-4 2.840 0.0191 (1.186, 6.798)
CD8
+ T cells w/CTLA-4 2.690 0.0273 (1.117, 6.474)
Actiated CD8
+ T cells 1.027 0.9316 (0.561, 1.878)
doi:10.1371/journal.pone.0032614.t003
Immune Monitoring after DC Vaccination
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survival of malignant glioma patients receiving DC vaccination. A recursive partitioning survival tree algorithm was utilized to dichotomize
the immune monitoring variables. The overall survival was then compared between patients above and below the cut-off point. (A) Kaplan-Meier
survival curve for the overall survival of patients stratified above and below a cut-off value of 0.8865 for Treg populations. **p=0.0074 by log-rank
test. (B) Kaplan-Meier survival curve for the overall survival of patients stratified above and below a cut-off value of 1.047 for the expression of CTLA-4
on CD3
+CD4
+ T cells. **p=0.0034 by log-rank test. (C) Kaplan-Meier survival curve for the overall survival of patients stratified above and below a cut-
off value of 0.8065 for the expression of CTLA-4 on CD3
+CD8
+ T cells. *p=0.0105 by log-rank test.
doi:10.1371/journal.pone.0032614.g005
Immune Monitoring after DC Vaccination
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tumor immune responsiveness [32]. Similarly, the blockade of
CTLA-4 or PD-1 may enhance vaccine-elicited immune responses
and anti-tumor activity [42,43,44]. Such recent findings lend
further credence to the idea that the relative balance between
inhibitory immune signals and activation may dictate the overall
anti-tumor immune response [24,45,46].
Our findings also have clinical applications to other immune
therapeutic approaches for glioblastoma. Given the increasingly
important role that immunoregulatory factors may play for
effective anti-tumor immunity, the dynamic monitoring of Treg
cell populations and/or negative co-stimulatory molecule expres-
sion on PBL populations before and after therapy may allow
groups to monitor treatment efficacy and predict survival. Such an
immune monitoring strategy can be generally applicable to various
immunotherapeutic strategies [30], as it is non-antigen specific and
may give important information regarding the balance of
inhibitory and activation signals critical for the anti-tumor
immune response.
In conclusion, a statistically significant relationship was found
between the fraction of Treg cells or dynamic expression of
CTLA-4 in peripheral blood T cells with survival in glioblastoma
patients treated with dendritic cell vaccination. These data suggest
that decreased ratios of Treg cells or CTLA-4 after DC
vaccination may be associated with good prognosis in this patient
population. In contrast, there was no significant relationship found
between lymphocyte activation markers and survival, suggesting
that inhibitory immune checkpoints may dominantly regulate anti-
tumor immune responses on peripheral blood lymphocytes after
DC vaccination. In future studies, blood drawn from patients
before and after treatment and can be used as a means of
predicting their response to various treatment modalities.
Adjuvant therapies targeting regulatory T cells may potentially
be used in conjunction with DC vaccine immunotherapy to
augment the immune response to such therapies.
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